Newer issues in mesothelioma chemotherapy

Journal of Thoracic Oncology

Volumn 1, Issue 2, 2006, Pages 177-179

  Vogelzang, Nicholas ^a   Pass, Harvey I ^b  

^a NEVADA CANCER INSTITUTE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; ERLOTINIB; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IMATINIB; METHOTREXATE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; RANPIRNASE; SEMAXANIB; THALIDOMIDE; TRIMETREXATE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; MESOTHELIOMA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; METHODOLOGY; PLEURA TUMOR; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 34247898917     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200602000-00015     Document Type: Conference Paper

References (19)

1. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: Past results and recent developments. Lung Cancer 2004;45(Suppl 1):S103-S119.
2. Vogelzang N, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
3. Kindler H, Millard F, Herndon JE, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-317.
4. Nowak A, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-496.
5. Maisano R, Caristi N, Toscano G, et al. Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: Results of a pilot study. Tumori 2001;87:391-393.
6. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patientswith malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2006;23:6881-6889.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer: National Cancer Institute of the United States, National Cancer Institute of Canada - New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
8. Byrne M, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260.
9. Herndon J, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
10. Edwards J, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems). Thorax 2000;55:731-735.
11. Rinaldi D. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 1999;26(Suppl 6):82-88.
12. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
13. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-3544.
14. 12 as front line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
15. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002.
16. Leland P, Raines RT. Cancer chemotherapy: Ribonucleases to the rescue. Chem Biol 2001;8:405-413.
17. Vogelzang N, Shin D, Costanzi J, et al. Phase III randomized trial of Onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): Analysis of survival (Abstract). Proc Am Soc Clin Oncol 2000;19:577a.
18. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.
19. Kindler HL. Moving beyond chemotherapy: Novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45(Suppl 1):S125-S127.